From: Emerging nanotechnology-based therapeutics to combat multidrug-resistant cancer
S. No | Nanoparticles (NPs) | Chemotherapeutic drugs | Experimental model | Mechanism of action | Ref |
---|---|---|---|---|---|
Quantum Dots (QDs) | |||||
1 | Elacridar conjugated QDs | Doxorubicin | Human hepatocellular carcinoma (Bel-7402/ADR Bel-7402/ADR cells) | Specific binding of QDs to P-gp efflux pump active site, inhibition of drug efflux and enhanced doxorubicin retention | [331] |
2 | MPA-COOH- CdTe QDs | – | Human breast cancer (SK-BR-3 cells) | Small size QDs interact with ABC efflux transporters and block efflux efficacy | [332] |
3 | Cysteamine-CdTe QDs | Daunorubicin and Gambogic acid | Lymphoblastoid cells (Raji, Raji/DNR) and BALB/c nude mice | Downregulation of P-gp protein expression, drug retention and enhanced apoptotic mechanism | [333] |
4 | CdTe-QDs | Daunorubicin | Human hepatocarcimoma (HepG2/ADM) cells and nude mice | Inhibition of P-gp drug efflux pumps and overexpression of apoptosis-related caspase proteins with inhibition of tumor development | [334] |
Multiwalled Carbon Nanotubes (MWCNTs) | |||||
5 | MWCNTs | N-Tamoxifen and Quercetin | Human breast cancer (MDA-MB-231 cells) and Wistar rats | N-TAM mediated P-gp inhibition and enhanced cellular uptake and cytotoxicity and control of tumor growth | [335] |
6 | P-gp antibody tagged-MWCNTs | – | Mouse fibroblast cells (T3T-MDR1 cells) and NCI/ADR-RES spheroids cells | P-gp specific cellular uptake of CNTs and enhanced phototoxicity in MDR cells | [306] |
7 | MWCNTs | – | Human hepatocarcinoma HepG2 cell line | Alteration of the mitochondrial membrane potential by elevated intracellular ROS, further inhibition of ABC-mediated efflux transporters | [336] |
Mesoporous nanoparticles | |||||
8 | PEI-PEG functionalized mesoporous NPs | P-gp specific siRNA (siP-gp) and Doxorubicin | Human breast cancer (MCF-7/MDR cells) and MCF-7/MDR xenograft mice | P-gp silencing, intracellular drug uptake and retention and inhibition of tumor growth | [337] |
9 | Mesoporous silica NPs | γ-secretase inhibitors (GSIs) | Cervical cancer (HeLa cells), Human embryonic kidney (HEK293 cells), Breast cancer (T47D, MDA-MB-231, SK-BR-3, MDA-MB-468, MCF-7 cells) and MDA-MB-231 xenograft mice | MSN-GSI nanoformulations actively block Notch signaling in intestinal cancer stem cells | [213] |
10 | FITC-mesoporous silica NPs | Camptothecin | Pancreatic cancer (PANC-1, Capan-1, AsPc-1), Colon cancer (SW480) and stomach cancer (MKN45) cells | Enhanced drug delivery within cells and drug-mediated apoptotic cell death | [338] |